相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Integration of DNA sequencing with population pharmacokinetics to improve the prediction of irinotecan exposure in cancer patients
Spinel Karas et al.
BRITISH JOURNAL OF CANCER (2022)
Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23) : a multicentre, randomised, open-label, phase 3 trial
Thierry Conroy et al.
LANCET ONCOLOGY (2021)
Uridine diphosphate glucuronosyltransferase 1A1
Glyn Steventon
XENOBIOTICA (2020)
Pre-therapeutic UGT1A1 genotyping to reduce the risk of irinotecan-induced severe toxicity: Ready for prime time
Emma C. Hulshof et al.
EUROPEAN JOURNAL OF CANCER (2020)
All You Need to Know About DPYD Genetic Testing for Patients Treated With Fluorouracil and Capecitabine: A Practitioner-Friendly Guide
Federico Innocenti et al.
JCO ONCOLOGY PRACTICE (2020)
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
A. Bardia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Pharmacogenetic clinical randomised phase II trial to evaluate the efficacy and safety of FOLFIRI with high-dose irinotecan (HD-FOLFIRI) in metastatic colorectal cancer patients according to their UGT1A 1 genotype
David Paez et al.
BRITISH JOURNAL OF CANCER (2019)
A UGT1A1 genotype-guided dosing study of modified FOLFIRINOX in previously untreated patients with advanced gastrointestinal malignancies
Manish R. Sharma et al.
CANCER (2019)
Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics
Femke M. de Man et al.
CLINICAL PHARMACOKINETICS (2018)
Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial
Rui-Hua Xu et al.
LANCET ONCOLOGY (2018)
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
T. Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Genotype-Guided Dosing Study of FOLFIRI plus Bevacizumab in Patients with Metastatic Colorectal Cancer
Giuseppe Toffoli et al.
CLINICAL CANCER RESEARCH (2017)
Irinotecan-induced toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses
J. M. Campbell et al.
PHARMACOGENOMICS JOURNAL (2017)
Cost Evaluation of Irinotecan-Related Toxicities Associated With the UGT1A1*28 Patient Genotype
R. Roncato et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)
The cost-effectiveness of UGT1A1 genotyping before colorectal cancer treatment with irinotecan from the perspective of the German statutory health insurance
Bettina Butzke et al.
ACTA ONCOLOGICA (2016)
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
E. Van Cutsem et al.
ANNALS OF ONCOLOGY (2016)
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial
Andrea Wang-Gillam et al.
LANCET (2016)
UGT1A1 genotype and irinotecan therapy: general review and implementation in routine practice
Marie-Christine Etienne-Grimaldi et al.
FUNDAMENTAL & CLINICAL PHARMACOLOGY (2015)
Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer
Toshiaki Watanabe et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2015)
A Phase I Study of UGT1A1*28/*6 Genotype-Directed Dosing of Irinotecan (CPT-11) in Korean Patients with Metastatic Colorectal Cancer Receiving FOLFIRI
Kyu-Pyo Kim et al.
ONCOLOGY (2015)
Dose escalating study of cetuximab and 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) in first line therapy of patients with metastatic colorectal cancer
Gunnar Folprecht et al.
BMC CANCER (2014)
UGT1A1*6 polymorphisms are correlated with irinotecan-induced toxicity: a system review and meta-analysis in Asians
Lei Cheng et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)
Dose-Finding and Pharmacokinetic Study to Optimize the Dosing of Irinotecan According to the UGT1A1 Genotype of Patients With Cancer
Federico Innocenti et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
Fotios Loupakis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Association of UGT1A1*28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: a meta-analysis in Caucasians
X. Liu et al.
PHARMACOGENOMICS JOURNAL (2014)
A genotype-directed phase I-IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer
E. Marcuello et al.
BRITISH JOURNAL OF CANCER (2011)
Clinical Implications of UGT1A1*28 Genotype Testing in Colorectal Cancer Patients
Katerina Shulman et al.
CANCER (2011)
Cetuximab Plus FOLFIRINOX (ERBIRINOX) as First-Line Treatment for Unresectable Metastatic Colorectal Cancer: A Phase II Trial
Eric Assenat et al.
ONCOLOGIST (2011)
UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy
E. Martinez-Balibrea et al.
BRITISH JOURNAL OF CANCER (2010)
Individualizing Dosing of Irinotecan
Mark J. Ratain et al.
CLINICAL CANCER RESEARCH (2010)
A Randomized, Placebo-Controlled Phase II Study Evaluating the Reduction of Neutropenia and Febrile Neutropenia in Patients With Colorectal Cancer Receiving Pegfilgrastim With Every-2-Week Chemotherapy
J. Randolph Hecht et al.
CLINICAL COLORECTAL CANCER (2010)
Generalizability of toxicity data from oncology clinical trials to clinical practice: toxicity of irinotecan-based regimens in patients with metastatic colorectal cancer
S. Dhesy-Thind et al.
Current Oncology (2010)
Genotype-Driven Phase I Study of Irinotecan Administered in Combination With Fluorouracil/Leucovorin in Patients With Metastatic Colorectal Cancer
Giuseppe Toffoli et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Cost Effectiveness of Pharmacogenetic Testing for Uridine Diphosphate Glucuronosyltransferase 1A1 Before Irinotecan Administration for Metastatic Colorectal Cancer
Heather Taffet Gold et al.
CANCER (2009)
Predictive Role of the UGT1A1, UGT1A7, and UGT1A9 Genetic Variants and Their Haplotypes on the Outcome of Metastatic Colorectal Cancer Patients Treated With Fluorouracil, Leucovorin, and Irinotecan
Erika Cecchin et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Comprehensive Pharmacogenetic Analysis of Irinotecan Neutropenia and Pharmacokinetics
Federico Innocenti et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Integrated pharmacogenetic prediction of irinotecan pharmacokinetics and toxicity in patients with advanced non-small cell lung cancer
Ji-Youn Han et al.
LUNG CANCER (2009)
Clinical and pharmacogenetic factors associated with irinotecan toxicity
Dinemarie Kweekel et al.
CANCER TREATMENT REVIEWS (2008)
Cost-effectiveness of UGT1A1 genotyping in second-line, high-dose, once every 3 weeks irinotecan monotherapy treatment of colorectal cancer
Marko Obradovic et al.
PHARMACOGENOMICS (2008)
UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan
Jean-Francois Cote et al.
CLINICAL CANCER RESEARCH (2007)
Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin
Ji-Youn Han et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Intestinal microflora and digestive toxicity of irinotecan in mice
G Brandi et al.
CLINICAL CANCER RESEARCH (2006)
Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan
F Innocenti et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Chemotherapy-induced neutropenia - Risks, consequences, and new directions for its management
J Crawford et al.
CANCER (2004)
Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups
F Innocenti et al.
PHARMACOGENETICS (2002)
Modulation of irinotecan metabolism by ketoconazole
DFS Kehrer et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Irinotecan in the treatment of colorectal cancer: Clinical overview
U Vanhoefer et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure
G. Freyer et al.
BRITISH JOURNAL OF CANCER (2000)
分享论文
